



P R E S S R E L E A S E

Alizé Pharma PREMAG project, supported by Lyonbiopole awarded by the LAB MEETING of Bref Rhône-Alpes

Lyon, 10 December 2015 - Lyonbiopole, the Rhône-Alpes region healthcare competitiveness cluster, participated at the first LAB MEETING of Bref, held on the occasion of the 10 years of Bref Rhône-Alpes Trophy of Innovation. Intended to promote SMEs that boost Rhône-Alpes economy, this event has associated competitiveness clusters, leaders and accelerators of innovation to reward particularly promising projects.

Among the 18 projects submitted by nine clusters of the Rhône-Alpes region, two were selected including Alizé Pharma PREMAG project rewarded during the Awards ceremony evening held on Wednesday, December 9 in Lyon.

PREMAG PROJECT

Single Inter-Ministry Fund project (FUI) co-accredited by 2 competitiveness clusters: Lyonbiopole (Rhône-Alpes region) and Medicen (Paris).

This project of nearly 4 million is part of AZP-531 Alizé Pharma program. It aims to develop a new drug with strong clinical and commercial potential based on knowledge of the effects of a hormone secreted by the stomach, ghrelin. The AZP-531, an analog of unacylated ghrelin (UAG), is in clinical development for type 2 diabetes and Prader-Willi syndrome.

The PREMAG objective is to develop AZP-531 and biomarkers for therapeutic applications as a cardioprotective agent and more generally in muscular protection and regeneration.

Partners

- Alizé Pharma (project leader), 69
- Hospices Civils de Lyon (HCL) - Pr. Michel Ovize, 69
- VetAgro Sup - Pr. Jeanne-Marie Bonnet, 69
- WIL Research, 69
- Bertin Pharma, 78

International collaborations

- Erasmus Medical Center - Pr. AJ van der Lely (Rotterdam, Netherlands)
- Torino University – Pr. Ezio Ghigo (Torino, Italy)

"We are very pleased that our collaborative PREMAG project was rewarded. We have key partners in their respective fields. The results will explore the potential of our analog of unacylated ghrelin (UAG) in complementary applications already indications targeted and in clinical development, type 2 diabetes and Prader Willi syndrome" says Thierry Abribat, Alizé Pharma CEO.



P R E S S R E L E A S E

"We are delighted that the PREMAG project was chosen for the quality of its research and its ambitions in the field of health. This is a perfect illustration of the opening and collaborative innovation which we encourage in our ecosystem" concludes Florence Agostino-Etchetto, Lyonbiopole CEO.

About Lyonbiopole

As a biocluster, Lyonbiopole is the gateway for healthcare innovation in Rhône-Alpes, France. It aims to support the emergence and development of innovative technologies, products and services in 4 main strategic areas: human medicine, veterinary medicine, *in vitro* diagnostics, medical devices and medical technologies. Focused on infectious diseases since its creation in 2005, Lyonbiopole is now supporting ambitious projects and companies in other fields like cancer, nutrition, metabolic diseases and neurosciences. In 2014, Lyonbiopole represented a community of 176 members: 4 world-class leaders as Lyonbiopole's founders (Sanofi Pasteur, bioMérieux, Merial, BD) – 18 Research Centers including 3 Hospital University Centers and almost 154 SMEs. Lyonbiopole received in November 2014, the Gold label awarded by the "European Cluster Excellence Initiative".

More information: www.lyonbiopole.com

Press Contacts

Marie-Caroline Saro - +33 1 58 18 32 58 – + 33 6 88 84 81 74 - mcsaro@comcorp.fr
Stéphanie Pelège - +33 4 72 76 53 41 – stephanie.pelege@lyonbiopole.com